Literature DB >> 3376178

Cyclosporin: erythrocyte binding and an examination of its use to estimate unbound concentration.

B Legg1, M Rowland.   

Abstract

Cyclosporin A (CyA) undergoes saturable binding to erythrocytes. Theoretically, measurement of erythrocyte concentration can be used to estimate the unbound concentration, which in turn may be more closely related to response than total plasma concentration. This possibility for estimating unbound concentration was explored in 139 blood samples taken from renal transplant patients who received CyA therapy. In practice, the method proved to be no better than that obtained by assuming a constant fraction CyA in plasma unbound. In this study, however, both methods were too imprecise to be of practical value. If unbound CyA concentration is to be determined it must be measured directly or must be estimated by multiplying total plasma concentration by fraction of drug unbound.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3376178

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  The binding of cyclosporin A to human plasma: an in vitro microdialysis study.

Authors:  H Yang; W F Elmquist
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

2.  Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

3.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

4.  Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective.

Authors:  Xiaoyan Qiu; Weiwei Qin; Junjun Mao; Luyang Xu; Ming Zhang; Mingkang Zhong
Journal:  Pharm Res       Date:  2021-11-08       Impact factor: 4.200

Review 5.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

7.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.

Authors:  R Kawai; M Lemaire; J L Steimer; A Bruelisauer; W Niederberger; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1994-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.